ArQule (ARQL) News Today → The Best AI Stock to Own in the World Today is Trading for Just $25 (From Banyan Hill Publishing) (Ad) Free ARQL Stock Alerts Notice: This company has been marked as potentially delisted and may not be actively trading. Add Compare Share Share HeadlinesStock Analysis All Sources Trusted Sources MarketBeat.com Benzinga Bloomberg MarketWatch Motley Fool NASDAQ PR Newswire Reuters Seeking Alpha The Street The Wall Street Journal Yahoo Finance Source Sentiment refers to the positivity or negativity of each headline according to our language processing algorithm. Sentiment All Sentiments Very Positive Positive Neutral Negative Very Negative SourceHeadlineMerck Sharp & Dohme Corp.'s Net Worthbenzinga.com - March 22 at 9:14 PMASCO Live Blog: Saturdaythestreet.com - June 30 at 8:18 PM2023 Fibroblast Growth Factor Receptor 2 Inhibitor Market Share and Growth Rate Forecast for 2030marketwatch.com - May 5 at 10:47 AMWelcome to My Portfolio - Link your brokers or add lotsfinance.yahoo.com - April 3 at 12:11 AM40+ Key Companies Actively Working in the Marginal Zone Lymphoma Pipeline Segment | DelveInsight - GlobeNewswireglobenewswire.com - September 21 at 6:03 PMForm SC 13E3 Stealth BioTherapeutics Filed by: Stealth BioTherapeutics Corp - StreetInsider.comstreetinsider.com - August 21 at 10:47 PMMerus Stock: Precision Oncology Pioneer Executes In The Clinic (NASDAQ:MRUS) - Seeking Alphaseekingalpha.com - June 30 at 12:05 PMAptose Reports Results for the First Quarter 2022 - GuruFocus.comgurufocus.com - June 18 at 6:41 PMAptose Biosciences Inc. (APTO) CEO Dr. William G. Rice on Q1 2022 Results - Earnings Call Transcript - Seeking Alphaseekingalpha.com - May 9 at 10:07 PMRENEWABLE ENERGY GROUP, INC. : Other Events (form 8-K) - Marketscreener.commarketscreener.com - May 9 at 5:06 PMAptose Reports Results for the First Quarter 2022 - Financial Postfinancialpost.com - May 9 at 5:06 PMForm DEF 14A Deciphera Pharmaceutical For: Jun 23 - StreetInsider.comstreetinsider.com - April 26 at 1:57 PMBasilea reports preclinical data on oncology drug candidates BAL0891, derazantinib and lisavanbulin at AACR Annual Meeting - GlobeNewswireglobenewswire.com - April 13 at 2:43 AMAPTOSE BIOSCIENCES INC. : Change in Directors or Principal Officers, Other Events, Financial Statements and Exhibits (form 8-K) - Marketscreener.commarketscreener.com - April 11 at 8:39 PMAptose Announces Executive Management Changes - StreetInsider.comstreetinsider.com - April 8 at 6:42 PMWest Pharmaceutical Services : Names President and CEO Eric M. Green as Chair of the Board - Form 8-K - marketscreener.commarketscreener.com - March 1 at 5:03 AMWest Names President and CEO Eric M. Green as Chair of the Board - PRNewswireprnewswire.com - February 28 at 4:49 PMBasilea to become a leading anti-infectives company backed - GlobeNewswireglobenewswire.com - February 15 at 1:47 AMHeartFlow Appoints Timothy Barabe to its Board of Directors - StreetInsider.comstreetinsider.com - January 20 at 9:32 AMHeartFlow Appoints Timothy Barabe to its Board of Directors - Yahoo Financefinance.yahoo.com - January 18 at 8:49 PMBasilea reports on portfolio progress made in 2021 - GlobeNewswireglobenewswire.com - January 6 at 9:53 AMCuris Adds Three New Executives to Management Team Strengthening Medical Affairs, Clinical Development and Clinical Operations - marketscreener.commarketscreener.com - January 3 at 8:08 AMSAVA Stock: 8 Things to Know as Cassava Sciences Rockets Higher - InvestorPlaceinvestorplace.com - November 2 at 5:41 PMBasilea presents preclinical data on synergy between derazantinib and paclitaxel in gastric tumor models at ANE Conference - Yahoo Financefinance.yahoo.com - October 11 at 1:27 AMEnlivex Therapeutics : NOTICE OF ANNUAL AND EXTRAORDINARY GENERAL MEETING OF SHAREHOLDERS ON (Form 6-K) - Marketscreener.commarketscreener.com - September 30 at 10:10 PMForm 6-K Enlivex Therapeutics For: Sep 30 - StreetInsider.comstreetinsider.com - September 30 at 10:10 PMMerck & Co., Inc. (MRK) Management Presents at European Society for Medical Oncology Virtual Congress 2021 (Transcript) - Seeking Alphaseekingalpha.com - September 21 at 3:57 AMBasilea presents full safety and efficacy data set on derazantinib in patients with FGFR2 fusion-positive iCCA at ESMO congress - StreetInsider.comstreetinsider.com - September 18 at 6:38 PMBasilea presents full safety and efficacy data set on derazantinib in patients with FGFR2 fusion-positive iCCA at ESMO congress - Yahoo Finance UKuk.finance.yahoo.com - September 17 at 5:35 PMBasilea presents full safety and efficacy data set on derazantinib in patients with FGFR2 fusion-positive iCCA at ESMO congress - Yahoo Financefinance.yahoo.com - September 17 at 12:34 PMBasilea presents full safety and efficacy data set on derazantinib in patients with FGFR2 fusion-positive - Benzingabenzinga.com - September 17 at 2:08 AMMerck & Co., Inc. (MRK) CEO Robert Davis Presents at Morgan Stanley 19th Annual Global Healthcare Conference (Transcript) - Seeking Alphaseekingalpha.com - September 13 at 5:42 PMInfinity Pharma Names Robert Ilaria As CMO And Brian Schwartz To Board - Quick Facts - Nasdaqnasdaq.com - September 7 at 4:55 PMInfinity Pharma (INFI) Appoints Robert Ilaria as Chief Medical Officer; Brian Schwartz to its Board - StreetInsider.comstreetinsider.com - September 7 at 8:33 AMBasilea reports strong financial results for half-year 2021 - GlobeNewswireglobenewswire.com - August 17 at 3:57 AMPress Release : Basilea reports strong financial -3- - Marketscreener.commarketscreener.com - August 17 at 3:57 AM Get ArQule News Delivered to You Automatically Sign up to receive the latest news and ratings for ARQL and its competitors with MarketBeat's FREE daily newsletter. Email Address The Gold Grab of the Century (Ad)When central banks buy gold… The rich buy right along with them. And central banks are buying at breakneck pace. Last year… 1,037 tons. Just 45 tons less than the record set two years ago. That's why we have released our Free Precious Metals Investment Guide. ARQL Media Mentions By Week ARQL Media SentimentLearn about the media sentiment score. Each headline receives a score ranging from 2 (good news) to -2 (bad news). Our company news sentiment scores track the average news sentiment of articles about each company over the most recent 7 days in order to identify companies that are receiving positive press. ARQL News Sentiment▼0.000.34▲Average Medical News Sentiment ARQL News CoverageLearn about the media coverage comparison. We track news headlines from hundreds of news outlets and tag them by company. This chart compares the number of articles about this company in the last seven days compared with the average number of articles about this company on a typical week. ARQL Articles This Week▼00▲ARQL Articles Average Week Get ArQule News Delivered to You Automatically Sign up to receive the latest news and ratings for ARQL and its competitors with MarketBeat's FREE daily newsletter. Email Address Related Companies and Tools Related Companies: Geron News Today Amicus Therapeutics News Today Dynavax Technologies News Today Ironwood Pharmaceuticals News Today Ligand Pharmaceuticals News Today MannKind News Today Innoviva News Today OPKO Health News Today Alkermes News Today Madrigal Pharmaceuticals News Today Headlines Tools: Trending Media MentionsHigh Media Sentiment StocksLive News FeedMarketBeat OriginalsStock Ideas This page (NASDAQ:ARQL) was last updated on 4/29/2024 by MarketBeat.com Staff From Our PartnersConflict In Israel Sends Gold Soaring ???? Here’s How To Get Your ShareColonial MetalsThe Best AI Stock to Own in the World Today is Trading for Just $25Banyan Hill PublishingThe #1 Biotech Stock to Have on Your Radar in 2024… Huge AlertsAI finds its first serious applicationWall Street StarHealthcare Takes A Big Step Forward With The Help Of AIThe Bull ReportDid You Get Your Free Bitcoin Yet?Crypto Swap ProfitsForget Bitcoin. Crypto Millionaire Predicts 8,788% Gains For THISParadigm PressThe A.I. story nobody is telling you (Read ASAP)TradeSmith Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding ArQule, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.